Booth Bruce sold $3.4M of KYMR (indirect holdings)
Booth Bruce sold 31,283 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at an average of $109.48 ($108.28–$111.20, $3.42M total) across 8 trades on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may briefly reassess sentiment around KYMR, but the 10b5-1 structure generally lowers the probability that the sale signals new negative information.
Market read
A newly filed insider sale for ~$3.42M is disclosed, but it is pre-arranged (10b5-1), so the actionable signal is modest.
What to watch
The article provides only the sale details; it does not include any concurrent buy activity, new guidance, or clinical/regulatory catalysts that would change fundamentals.
Background
The article is an SEC Form 4 insider transaction: director Booth Bruce sold Kymera Therapeutics shares via open-market sales under a pre-arranged 10b5-1 plan.
Ticker impact
Kymera Therapeutics director Booth Bruce sold 31,283 shares in open-market trades for ~$3.42M under a 10b5-1 plan on 2026-06-29.
Likely limited immediate price impact; any effect would be sentiment-driven and should fade unless accompanied by other catalysts.
The filing is a primary Form 4 disclosure with a defined sale window and explicit 10b5-1 pre-arrangement, reducing interpretive weight versus non-10b5-1 sales.
Market effects
No direct sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity/compensation mechanics rather than bearish expectations.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; director Booth Bruce sold shares under a 10b5-1 plan.
- insiderBooth Bruce
Director who executed open-market sales totaling ~$3.42M across 8 trades on 2026-06-29.
